Carotuximab: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
WildCation (talk | contribs) Chembox edits: Set CSID to none |
||
Line 41: | Line 41: | ||
| UNII = YB2EWE6139 |
| UNII = YB2EWE6139 |
||
| synonyms = TRC-105 |
| synonyms = TRC-105 |
||
| ChemSpiderID = none |
|||
}} |
}} |
||
Revision as of 12:48, 17 April 2018
Monoclonal antibody | |
---|---|
Type | ? |
Source | Chimeric (mouse/human) |
Target | endoglin |
Clinical data | |
Other names | TRC-105 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6420H9922N1718O2010S46 |
Molar mass | 144.8 g/mol g·mol−1 |
Carotuximab (INN[1]) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
This drug was developed by Tracon Pharmaceuticals Inc.[2]
It is at Phase III trials for angiosarcoma.